However, two subsequent trials that were planning to evaluate the combination of INO-3112 and Durvalumab (Imfinzi, AstraZeneca, Cambridge, United Kingdom), a PD-L1 antibody, in patients with R/M heavily treated HPV-16/-18+ HNSCC (NCT03162224) and in the adjuvant setting of HPV-16+ OPSCC (NCT04001413), have been terminated (after partial accrual) and withdrawn, respectively. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.